uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in Sweden
Department of Economics, Centre for Health Economics, University of Gothenburg, Sweden.
Pfizer AB, Sollentuna, Stockholm, Sweden.
Pfizer, Endocrine Care, Pfizer Inc, Sollentuna, Sweden . (Barnendokrinologisk forskning/Gustafsson)
Pfizer Ltd, Walton Oaks, UK.
Show others and affiliations
2013 (English)In: Cost Effectiveness and Resource Allocation, ISSN 1478-7547, E-ISSN 1478-7547, Vol. 11, no 1, 24- p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND:

To evaluate the cost-effectiveness of growth hormone (GH) treatment (Genotropin(R)) compared with no GH treatment in adults with GH deficiency in a Swedish societal setting.

METHODS:

A Markov-type cost-utility simulation model was constructed and used to simulate, for men and women, morbidity and mortality for GH-treated and -untreated individuals over a 20-year period. The calculations were performed using current available prices concerning morbidity-related healthcare costs and costs for Genotropin(R). All costs and treatment effects were discounted at 3%. Costs were expressed in Euro (1[euro sign] = 9.03 SEK). GH-treated Swedish patients (n = 434) were identified from the KIMS database (Pfizer International Metabolic Database) and untreated patients (n = 2135) from the Swedish Cancer Registry and the Hospital Discharge Registry.

RESULTS:

The results are reported as incremental cost per quality-adjusted life year (QALY) gained, including both direct and indirect costs for GH-treated versus untreated patients. The weighted sum of all subgroup incremental cost per QALY was [euro sign]15,975 and [euro sign]20,241 for men and women, respectively. Including indirect cost resulted in lower cost per QALY gained: [euro sign]11,173 and [euro sign]10,753 for men and women, respectively. Key drivers of the results were improvement in quality of life, increased survival, and intervention cost.

CONCLUSIONS:

The incremental cost per QALY gained is moderate when compared with informal thresholds applied in Sweden. The simulations suggest that GH-treatment is cost-effective for both men and women at the [euro sign]55,371 (SEK 500,000 -- the informal Swedish cost-effectiveness threshold) per QALY threshold.

Place, publisher, year, edition, pages
2013. Vol. 11, no 1, 24- p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-209687DOI: 10.1186/1478-7547-11-24PubMedID: 24079522OAI: oai:DiVA.org:uu-209687DiVA: diva2:659075
Available from: 2013-10-24 Created: 2013-10-24 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

fulltext(451 kB)158 downloads
File information
File name FULLTEXT01.pdfFile size 451 kBChecksum SHA-512
9fec31390b9865f04dd30121e1943e05c88a004709ceeaa0150450e3c281df6932feeeaad09dfeba072d838134ce5123ade76f30925572e6ed6fe795c50ebf2e
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Koltowska-Häggström, MariaJonsson, Björn

Search in DiVA

By author/editor
Koltowska-Häggström, MariaJonsson, Björn
By organisation
Department of Women's and Children's Health
In the same journal
Cost Effectiveness and Resource Allocation
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 158 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 694 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf